Belgrade

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis3 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 trials
• Crohn's disease1 trial
• Pompe disease1 trial
• Ulcerative colitis1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Completed4 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Enrolling by invitation1 trial

Lead sponsor

• Sanofi6 trials
• Bioverativ, a Sanofi company1 trial
• Genzyme, a Sanofi Company1 trial

Running trials

• Recruiting

  A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07185009· Phase 3· Sanofi· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184931· Phase 3· Sanofi· Source

• Enrolling by invitation

  Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

  NCT06859099· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

  NCT06372145· Phase 3· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Crohn's disease1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT04658472· Phase 2· Bioverativ, a Sanofi company· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

  NCT04410991· Phase 3· Sanofi· Source

• Recruiting

  Pompe Disease Registry Protocol

  NCT00231400· Genzyme, a Sanofi Company· Source

  Contact: Pompe Registry HelpLine